Tilray Brands

Tilray Brands rose 5.03% during the regular session to close at $4.075, driven by earnings season anticipation and business expansion news. The stock rebounded from an intraday low of $3.91 in early trading, climbing steadily, though post-market trading saw it ease back to $3.91. Q3 revenue grew 11.28% YoY to $206.7 million, while net loss narrowed 96.63% YoY to $26.57 million. However, the stock remains below its 20-day MA of $4.323 and 60-day MA of $4.951, with a YTD decline of 58.08% and 74.04% below its 52-week high of $15.7. Post-market volume was thin at 34,511 shares, suggesting caution ahead of the earnings report.

Tilray Brands closed the regular session at $3.99 on Tuesday, down 4.1% from the prior close of $4.16, after touching an intraday low of $3.93 and staging a modest recovery. The stock opened weak after a pre-market high of $4.22, falling below the $4 threshold and now trading 74.6% below its 52-week high of $15.7, well under both its 20-day MA of $4.38 and 60-day MA of $5.03, indicating persistent technical weakness. Recent developments—including Revolver Beer & Spirits' expansion of the Blood & Honey brand into whiskey, gin, and vodka, and plans to launch medical cannabis in Panama—failed to lift sentiment. For Q3 2026, revenue rose 11.3% YoY to $206.7 million and net loss narrowed 96.6% to $26.6 million, yet EPS of -$0.24 and a PB ratio of just 0.3x reflect low market tolerance for persistent losses. However, volume of ~3.98 million shares and a turnover rate of 3.4% suggest selling pressure was not extreme.

Tilray Brands experienced a single-session decline on Monday, trading at $4.389 as of 10:19 ET, down approximately 5.0% from the prior close of $4.620, primarily driven by dilution concerns after the issuance of 2,638,341 shares in exchange for $12 million of convertible notes due 2027, announced late Friday. The stock briefly surged to $4.730 in pre-market before reversing sharply. Financially, Q3 2026 EPS improved to -$0.240 (up 97.24% YoY) while revenue rose 11.28% to $206.7 million, though net margin remained negative at -12.85%. Meanwhile, concerns over BrewDog's declining UK sales are clouding the beverage segment outlook. The stock is currently trading 72.04% below its 52-week high of $15.70 and has fallen 54.85% YTD, persistently trading below both its MA20 ($4.753) and MA60 ($5.597).

Tilray Brands traded higher during regular hours, reaching $4.660 as of ET 09:36, up 5.19% from the prior close of $4.430, driven by news of issuing 2.63 million shares to exchange $12 million of convertible notes due 2027 and court approval for the acquisition of HelloMD's Canadian medical cannabis assets. The stock opened at $4.480 and climbed steadily, with an intraday high of $4.660 and a low of $4.515 at the open. Despite today's gain, the stock remains 70.29% below its 52-week high of $15.70 and trades below both the 20-day MA of $4.795 and 60-day MA of $5.637, with a YTD decline of 52.01%. Q3 net loss narrowed 96.63% YoY to $26.572 million, operating loss improved 36.58%, and revenue grew 11.28% YoY to $206.732 million. However, after-hours trading slipped back to $4.430, suggesting limited upward conviction.